Congress orders lung cancer research review for women, underserved groups

What it does

This bill directs the Secretary of Health and Human Services, working with the Departments of Defense and Veterans Affairs, to study the current state of lung cancer research focused on women and underserved populations, identify gaps in knowledge, and recommend ways to expand access to preventive screening and public education. The Secretary must report findings to Congress within two years.

Why we flagged it

The bill is a straightforward mandate for a government health agency to conduct a review and report on a specific public health research area. It contains no funding mechanism, no regulatory change, and no private-sector carve-out—only a directive to study and recommend.

What the text implies

• The two-year timeline may delay actionable recommendations; if Congress does not act on findings, the review becomes a historical record with no binding follow-up.
• The bill does not appropriate funds for the review itself or for implementing recommendations, leaving resource allocation to existing agency budgets and future legislative action.
• Inclusion of DoD and VA suggests potential focus on lung cancer in military and veteran populations, which may receive disproportionate attention relative to civilian underserved groups.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill mandates a comprehensive, interagency assessment of lung cancer research gaps and screening access specifically for women and underserved populations—groups historically underrepresented in medical research. The resulting report and recommendations may inform future policy and resource allocation to improve early detection and outcomes in these populations.

Named in the bill

Department of Health and Human Services, Department of Defense, Department of Veterans Affairs, United States Preventive Services Task Force, Congress

Where it stands

2 cosponsors: 2 Republicans.

• Mar 25, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 25, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
• Apr 29, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Apr 29, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported by Voice Vote”
• Apr 21, 2026 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H3020)”
• Apr 21, 2026 — Floor vote scheduled · Congress.gov: “Mrs. Harshbarger moved to suspend the rules and pass the bill”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 9 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $5,436,153 in lobbying spend. A filing names 35 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Brendan Boyle, the sponsor, reported $1,060,827 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• American Association of Nurse Practitioners — $950,000 on 2 filings
• Daiichi Sankyo Inc — $380,000 on 1 filing
• The Society of Thoracic Surgeons — $366,153 on 2 filings
• Hadassah, the Women's Zionist Organization of America, Inc. — $120,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.